Literature DB >> 35507118

Clinical outcomes following surgical management of insertional Achilles tendinopathy using a double-row suture bridge technique with mean two-year follow-up.

T L Lewis1, T Srirangarajan2, A Patel2, G C K Yip2, L Hussain2, R Walker2, S Singh2, A Latif2, A Abbasian2.   

Abstract

BACKGROUND: The clinical outcomes following surgical management of insertional Achilles tendinopathy (IAT) vary depending on the surgical technique used to reattach the Achilles tendon following debridement. The aim of this study was to investigate the clinical outcomes of patients with IAT who underwent surgical management with a double-row suture bridge technique used to reattach the Achilles tendon.
METHODS: A retrospective review of consecutive patients diagnosed with IAT, who underwent surgical management utilising a double-row suture bridge technique (Arthex Speedbridge), and a minimum of 3-month follow-up were included. The primary outcome was the Manchester-Oxford Foot Questionnaire (MOXFQ) Index score which is a patient reported outcome measure (PROM). Secondary outcomes included EuroQol EQ-5D-5L health-related quality of life PROM and complication rates.
RESULTS: Between July 2013 and June 2020, 50 consecutive patients (23 male; 27 female) were included. The mean age (± standard deviation) was 52.3 ± 11.3 (range 29.0-84.3). Pre- and post-operative PROM data were available for all cases. The mean follow-up was 2.4 ± 1.9 years. The MOXFQ Index score improved from 48.5 to 12.4 (p < 0.01), EQ-5D-5L improved from 2.7 ± 0.46 to 1.2 ± 0.37 (p < 0.01), and EQ-VAS improved from 48.0 ± 18.4 to 84.1 ± 12.6 (p < 0.01). Four patients had complications which were of minimal clinical relevance and caused no deviation from routine recovery. There were no cases of tendon rupture.
CONCLUSION: This study has demonstrated that surgical management of IAT is safe and effective with clinical improvement in both clinical and general health-related quality of life outcome PROMs. LEVEL OF EVIDENCE: IV.
© 2022. The Author(s), under exclusive licence to Springer-Verlag France SAS, part of Springer Nature.

Entities:  

Keywords:  Achilles tendon; Haglund deformity; Insertional Achilles tendinopathy; Patient-reported outcome measure; Speedbridge; Suture anchor repair; Tendon repair

Year:  2022        PMID: 35507118     DOI: 10.1007/s00590-022-03270-7

Source DB:  PubMed          Journal:  Eur J Orthop Surg Traumatol        ISSN: 1633-8065


  6 in total

1.  Biomechanical evaluation of arthroscopic rotator cuff repairs: double-row compared with single-row fixation.

Authors:  C Benjamin Ma; Lyn Comerford; Joseph Wilson; Christian M Puttlitz
Journal:  J Bone Joint Surg Am       Date:  2006-02       Impact factor: 5.284

Review 2.  Surgical Takedown Approaches to Insertional Achilles Tendinopathy: A Systematic Review.

Authors:  John M Thompson; Kevin Nguyen; Jaime Ahluwalia; Dominick Casciato; Tyler Tewilliager; Eric So; Mark Prissel
Journal:  J Foot Ankle Surg       Date:  2021-04-30       Impact factor: 1.286

3.  Minimally Invasive Distal Metatarsal Metaphyseal Osteotomy of the Lesser Toes: Clinical, Radiologic, and Pedobarographic Outcomes.

Authors:  Elena Neunteufel; Sabine Krenn; Michel Chraim; Pascal Amann; Fabian Greiner; Andreas Kranzl; Peter Bock
Journal:  Foot Ankle Int       Date:  2021-08-17       Impact factor: 2.827

4.  The Clavien-Dindo complication classification modified for foot and ankle orthopaedic surgery.

Authors:  T L Lewis; L Mason; D Gordon; R Ray
Journal:  Foot Ankle Surg       Date:  2022-03-19       Impact factor: 2.840

5.  Functional Outcomes of Insertional Achilles Tendinopathy Treatment: A Systematic Review.

Authors:  Ian J Jarin; Henrik C Bäcker; J Turner Vosseller
Journal:  JBJS Rev       Date:  2021-06-14

6.  Patient-Reported Outcomes of Surgically Treated Insertional Achilles Tendinopathy.

Authors:  Hubert Hörterer; Sonja Oppelt; Wolfgang Böcker; Oliver Gottschalk; Norbert Harrasser; Markus Walther; Hans Polzer; Sebastian Felix Baumbach
Journal:  Foot Ankle Int       Date:  2021-06-22       Impact factor: 2.827

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.